China pharma events break attendance records
Continued growth is a testament to the strength of the Chinese pharma market, says organiser
A record attendance of 26,547 is reported for the UBM International Media/UBM Sinexpo 2010 Chinese Pharma events cluster: CPhI China for intermediates and APIs; P-MEC for equipment and machinery; plus trails for ICSE Contract Services; and BioPh for the biopharma sector. This represents an increase of 12.3% over 2009 attendance levels.
The number of international visitors to the co-located events, which took place from 2-4 June at the Shanghai New International Expo Centre, saw an increase of 13% compared with 2009.
Exhibitor figures were also higher at the 2010 events: 1,391 exhibitors at CPhI China and 330 at P-MEC China, from a total of 18 countries. On-site space bookings for the 2011 events, scheduled for 21-23 June 2011, again at Shanghai New International Expo Centre, are at record levels, with both existing and new exhibitors signing up in line with rapidly accelerating market growth.
‘The continued growth of our China events is testament to the strength of the Chinese pharma market, which is projected to be the third largest pharma market globally by 2011 and second largest by 2020,’ said Eliane van Doorn, UBM International Media’s group director for pharma events. ‘We have witnessed significant growth in the number of Western visitors year-on-year, and the fact that we saw an increase of 13% at this year’s events is a reflection of changes within the industry, such as those to local GMP standards, which make sourcing in China increasingly appealing.
‘Factors such as these simply add to the attraction of the many outsourcing and production efficiency partnering opportunities for which China is already globally renowned. This growing demand for outsourcing of contract services has led us to introduce a dedicated ICSE pavilion for the 2011 event.’
In addition to the exhibition and networking elements, CPhI China offered more than 25 seminars and presentations, which focused on dynamic changes in the Chinese pharmaceutical market and US Quality Standards. Highlights included keynote speakers from Roche, Hovione, Wuxi AppTec and the FDA, while a panel discussion carried out a SWOT analysis of the current outsourcing market in China.
